• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Clinical, molecular, and prognostic comparisons between CCUS and lower-risk MDS: a study of 187 molecularly annotated patients.CCUS与低风险骨髓增生异常综合征之间的临床、分子及预后比较：一项对187例分子注释患者的研究
Blood Adv. 2021 Apr 27;5(8):2272-2278. doi: 10.1182/bloodadvances.2020003976.
2
A Lower Frequency of Spliceosome Mutations Distinguishes Clonal Cytopenias of Undetermined Significance From Low-Risk Myelodysplastic Syndromes, Despite Inherent Similarities in Genomic, Laboratory, and Clinical Features.剪接体突变的低频率可将意义未明的克隆性血细胞减少症与低危骨髓增生异常综合征区分开来，尽管在基因组、实验室和临床特征方面存在内在相似性。
Mod Pathol. 2023 Mar;36(3):100068. doi: 10.1016/j.modpat.2022.100068. Epub 2023 Jan 10.
3
Clinical implications and genetic features of clonal cytopenia of undetermined significance compared to lower-risk myelodysplastic syndrome.与低危骨髓增生异常综合征相比，克隆性血细胞减少症的临床意义和遗传特征。
Br J Haematol. 2022 Aug;198(4):703-712. doi: 10.1111/bjh.18273. Epub 2022 May 25.
4
Myelodysplastic Syndromes Diagnosis: What Is the Role of Molecular Testing?骨髓增生异常综合征的诊断：分子检测的作用是什么？
Curr Hematol Malig Rep. 2015 Sep;10(3):282-91. doi: 10.1007/s11899-015-0270-5.
5
Morphologic, immunophenotypic, and molecular genetic comparison study in patients with clonal cytopenia of undetermined significance, myelodysplastic syndrome, and acute myeloid leukemia with myelodysplasia-related changes: A single institution experience.在具有未确定意义的克隆性血细胞减少症、骨髓增生异常综合征和伴有骨髓增生异常相关变化的急性髓系白血病患者中进行形态学、免疫表型和分子遗传学比较研究：单机构经验。
Int J Lab Hematol. 2022 Aug;44(4):738-749. doi: 10.1111/ijlh.13840. Epub 2022 Mar 29.
6
Flow Cytometric Findings in Clonal Cytopenia of Undetermined Significance.克隆性血细胞减少症意义未明的流式细胞术检测结果。
Am J Clin Pathol. 2022 Feb 3;157(2):219-230. doi: 10.1093/ajcp/aqab116.
7
[Molecular Markers of Prognosis in Myelodysplastic Syndromes--Review].[骨髓增生异常综合征预后的分子标志物——综述]
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2016 Feb;24(1):285-9. doi: 10.7534/j.issn.1009-2137.2016.01.055.
8
Recurrent Cytogenetic Abnormalities in Myelodysplastic Syndromes.骨髓增生异常综合征中的复发性细胞遗传学异常
Methods Mol Biol. 2017;1541:209-222. doi: 10.1007/978-1-4939-6703-2_18.
9
Distinct mutation profile and prognostic relevance in patients with hypoplastic myelodysplastic syndromes (h-MDS).低增生性骨髓增生异常综合征（h-MDS）患者的独特突变谱及其预后相关性。
Oncotarget. 2016 Sep 27;7(39):63177-63188. doi: 10.18632/oncotarget.11050.
10
Mutations in myelodysplastic syndromes: Core abnormalities and CHIPping away at the edges.骨髓增生异常综合征中的突变：核心异常和边缘缺失。
Int J Lab Hematol. 2020 Dec;42(6):671-684. doi: 10.1111/ijlh.13284. Epub 2020 Aug 5.

引用本文的文献

1
Target practice: Opportunities for therapeutic intervention in CHIP and CCUS.靶向实践：CHIP和CCUS中的治疗干预机会。
Blood Rev. 2025 Jul 25:101323. doi: 10.1016/j.blre.2025.101323.
2
Advancing drug development in myelodysplastic syndromes.推动骨髓增生异常综合征的药物研发
Blood Adv. 2025 Mar 11;9(5):1095-1104. doi: 10.1182/bloodadvances.2024014865.
3
Implications of Clonal Hematopoiesis in Hematological and Non-Hematological Disorders.克隆性造血在血液系统和非血液系统疾病中的意义
Cancers (Basel). 2024 Dec 9;16(23):4118. doi: 10.3390/cancers16234118.
4
A blueprint for pursuing therapeutic interventions and early phase clinical trials in clonal haematopoiesis.克隆性造血中治疗干预及早期临床试验的开展蓝图。
Br J Haematol. 2025 Feb;206(2):416-427. doi: 10.1111/bjh.19925. Epub 2024 Dec 9.
5
Can molecular patterns help to classify overlapping entities in myeloid neoplasms?分子模式能否有助于对髓系肿瘤中的重叠实体进行分类？
Histopathology. 2025 Jan;86(1):146-157. doi: 10.1111/his.15339. Epub 2024 Oct 21.
6
High-dose IV ascorbic acid therapy for patients with CCUS with TET2 mutations.针对伴有TET2突变的慢性粒单核细胞白血病患者的大剂量静脉注射维生素C疗法。
Blood. 2024 Dec 5;144(23):2456-2461. doi: 10.1182/blood.2024024962.
7
Diagnostic and Practical Challenges in Applying National Comprehensive Cancer Network Guidelines for Suspected Pathogenic TP53 Mosaicism.应用国家综合癌症网络指南诊断和处理疑似致病性 TP53 嵌合体的实际挑战。
JCO Precis Oncol. 2024 Jul;8:e2400006. doi: 10.1200/PO.24.00006.
8
Clonal Hematopoiesis in Patients With Neuroendocrine Tumor Treated With Lutetium-177 and the Risk of Thrombocytopenia: A Prospective Study.镥-177 治疗神经内分泌肿瘤患者的克隆性造血与血小板减少症风险：一项前瞻性研究。
JCO Precis Oncol. 2024 Jun;8:e2400143. doi: 10.1200/PO.24.00143.
9
Genomic landscape of CCUS compared to MDS and its implications on risk prediction.与骨髓增生异常综合征相比，碳捕获、利用与封存技术的基因组格局及其对风险预测的影响。
Leukemia. 2024 Jul;38(7):1634-1637. doi: 10.1038/s41375-024-02273-z. Epub 2024 May 10.
10
The impact of cytotoxic therapy on the risk of progression and death in clonal cytopenia(s) of undetermined significance.细胞毒性治疗对未确定意义的克隆性细胞减少症进展和死亡风险的影响。
Blood Adv. 2024 Jun 25;8(12):3130-3139. doi: 10.1182/bloodadvances.2023012357.

本文引用的文献

1
Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a focused review.骨髓增生异常综合征/骨髓增殖性肿瘤重叠综合征：重点综述。
Hematology Am Soc Hematol Educ Program. 2020 Dec 4;2020(1):460-464. doi: 10.1182/hematology.2020000163.
2
Myelodysplastic Syndromes.骨髓增生异常综合征
N Engl J Med. 2020 Oct 1;383(14):1358-1374. doi: 10.1056/NEJMra1904794.
3
Assessing clonal haematopoiesis: clinical burdens and benefits of diagnosing myelodysplastic syndrome precursor states.评估克隆性造血：诊断骨髓增生异常综合征前驱状态的临床负担与益处
Lancet Haematol. 2020 Jan;7(1):e73-e81. doi: 10.1016/S2352-3026(19)30211-X. Epub 2019 Dec 3.
4
Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391-2405.阿伯尔·D·A、奥拉齐·A、哈塞尔简·R等。《世界卫生组织髓系肿瘤和急性白血病分类（2016年修订版）》。《血液》。2016年；127(20):2391 - 2405。
Blood. 2016 Jul 21;128(3):462-463. doi: 10.1182/blood-2016-06-721662.
5
Clinical Applications and Utility of a Precision Medicine Approach for Patients With Unexplained Cytopenias.精准医疗方法在不明原因血细胞减少症患者中的临床应用及实用性。
Mayo Clin Proc. 2019 Sep;94(9):1753-1768. doi: 10.1016/j.mayocp.2019.04.007. Epub 2019 Jun 27.
6
Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials.临床试验中修订 MDS 患者 IWG 2018 血液学反应标准的建议。
Blood. 2019 Mar 7;133(10):1020-1030. doi: 10.1182/blood-2018-06-857102. Epub 2018 Nov 7.
7
Practical recommendations for reporting Fine-Gray model analyses for competing risk data.关于报告竞争风险数据的Fine-Gray模型分析的实用建议。
Stat Med. 2017 Nov 30;36(27):4391-4400. doi: 10.1002/sim.7501. Epub 2017 Sep 15.
8
Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease.克隆性造血与动脉粥样硬化性心血管疾病风险
N Engl J Med. 2017 Jul 13;377(2):111-121. doi: 10.1056/NEJMoa1701719. Epub 2017 Jun 21.
9
Clinical significance of somatic mutation in unexplained blood cytopenia.不明原因血细胞减少症中体细胞突变的临床意义。
Blood. 2017 Jun 22;129(25):3371-3378. doi: 10.1182/blood-2017-01-763425. Epub 2017 Apr 19.
10
Dynamics of clonal evolution in myelodysplastic syndromes.骨髓增生异常综合征的克隆进化动力学
Nat Genet. 2017 Feb;49(2):204-212. doi: 10.1038/ng.3742. Epub 2016 Dec 19.

Clinical, molecular, and prognostic comparisons between CCUS and lower-risk MDS: a study of 187 molecularly annotated patients.

作者信息

Li Marissa, Binder Moritz, Lasho Terra, Ferrer Alejandro, Gangat Naseema, Al-Kali Aref, Mangaonkar Abhishek, Elliott Michelle, Litzow Mark, Hogan William, Pardanani Animesh, Wolanskyj-Spinner Alexandra, Howard Matthew, King Rebecca L, Shah Mithun, Alkhateeb Hassan, Begna Kebede, Tefferi Ayalew, Finke Christy, Oliveira Jennifer, Ketterling Rhett, Olteanu Horatiu, Patnaik Mrinal M

机构信息

Department of Internal Medicine.

Division of Hematology, Department of Medicine, and.

出版信息

Blood Adv. 2021 Apr 27;5(8):2272-2278. doi: 10.1182/bloodadvances.2020003976.

DOI:10.1182/bloodadvances.2020003976
PMID:33904893
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8095155/
Abstract
摘要